Potent and selective P2Y12
receptor antagonist. Blocks ADP-induced inhibition of adenylyl cyclase in vitro
=7.6) and inhibits ADP-induced aggregation of washed human platelets (pIC50
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from AstraZeneca
FPL 66096: a novel, highly potent and selective antagonist at human platelet P2T-purinoceptors.
Humphries et al.
Antagonists of the platelet P receptor: a novel approach to antithrombotic therapy.
Ingall et al.
Activity of adenosine diphosphates and triphosphates on a P2YT-type receptor in brain capillary endothelial cells.
Simon et al.
The citations listed below are publications that use Tocris products. Selected citations for AR-C 66096 tetrasodium salt include:
Showing Results 1 - 4 of 4